Ⅰ期滤泡性淋巴瘤的基因组与微环境特征及其与Ⅲ/Ⅳ期的比较
该研究采用二代测序和免疫组化分析82例Ⅰ期淋巴结滤泡性淋巴瘤(FL)病例,并与139例Ⅲ/Ⅳ期淋巴结FL病例比较。结果显示两组在突变、染色体拷贝数异常和微环境细胞群方面存在许多相似性,但也存在显著差异:Ⅰ期FL中CD8+ T细胞(P = .02)和STAT6突变(FDR <0.001)更常见;而Ⅲ/Ⅳ期FL中程序性细胞死亡蛋白1阳性T细胞、CD68+/CD163+巨噬细胞(P < .001)、BCL2易位(BCL2trl+)(P < .0001)以及KMT2D(FDR = 0.003)和CREBBP(FDR = 0.04)突变更常见。聚类分析在Ⅰ期内识别出3个簇,在Ⅲ/Ⅳ期内识别出2个簇;BCL2trl+的Ⅰ期簇与Ⅲ/Ⅳ期BCL2trl+簇相当,两个BCL2trl-的Ⅰ期簇为Ⅰ期所独有。该探索性研究显示Ⅰ期FL具有遗传异质性,存在不同的致癌通路;Ⅰ期FL BCL2trl-可能由STAT6驱动,而Ⅲ/Ⅳ期BCL2trl-似乎更多由BCL6trl驱动。
要点
- Ⅰ期FL中CD8+ T细胞(P = .02)和STAT6突变(FDR <0.001)更常见。
- Ⅲ/Ⅳ期FL中PD-1阳性T细胞、CD68+/CD163+巨噬细胞(P < .001)、BCL2易位(P < .0001)、KMT2D(FDR = 0.003)和CREBBP(FDR = 0.04)突变更常见。
- Ⅰ期FL BCL2trl-可能由STAT6驱动,而Ⅲ/Ⅳ期BCL2trl-似乎更多由BCL6trl驱动。
核心结论
- 该探索性研究显示Ⅰ期FL具有遗传异质性,存在不同的致癌通路;Ⅰ期FL BCL2trl-可能由STAT6驱动,而Ⅲ/Ⅳ期BCL2trl-似乎更多由BCL6trl驱动。
研究设计与样本
- 采用二代测序和免疫组化分析82例Ⅰ期淋巴结FL病例,并与139例Ⅲ/Ⅳ期淋巴结FL病例进行比较。
主要发现
- Ⅰ期FL中CD8+ T细胞(P = .02)和STAT6突变(FDR <0.001)更常见。
- Ⅲ/Ⅳ期FL中程序性细胞死亡蛋白1阳性T细胞、CD68+/CD163+巨噬细胞(P < .001)、BCL2易位(BCL2trl+)(P < .0001)以及KMT2D(FDR = 0.003)和CREBBP(FDR = 0.04)突变更常见。
- 聚类分析在Ⅰ期内识别出3个簇,在Ⅲ/Ⅳ期内识别出2个簇;BCL2trl+的Ⅰ期簇与Ⅲ/Ⅳ期BCL2trl+簇相当。
- 两个BCL2trl-的Ⅰ期簇为Ⅰ期所独有:一个富集CREBBP(95%)和STAT6(64%)突变,无BCL6易位(BCL6trl);另一个相对异质,有更多拷贝数异常和连接组蛋白突变。
- BCL2trl-的Ⅲ/Ⅳ期簇包含BCL6trl(64%),CREBBP(45%)和STAT6(9%)突变较少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although the genomic and immune microenvironmental landscape of follicular lymphoma (FL) has been extensively investigated, little is known about the potential biological differences between stage I and stage III/IV disease. Using next-generation sequencing and immunohistochemistry, 82 FL nodal stage I cases were analyzed and compared with 139 FL stage III/IV nodal cases. Many similarities in mutations, chromosomal copy number aberrations, and microenvironmental cell populations were detected. However, there were also significant differences in microenvironmental and genomic features. CD8+ T cells (P = .02) and STAT6 mutations (false discovery rate [FDR] <0.001) were more frequent in stage I FL. In contrast, programmed cell death protein 1-positive T cells, CD68+/CD163+ macrophages (P < .001), BCL2 translocation (BCL2trl+) (P < .0001), and KMT2D (FDR = 0.003) and CREBBP (FDR = 0.04) mutations were found more frequently in stage III/IV FL. Using clustering, we identified 3 clusters within stage I, and 2 clusters within stage III/IV. The BLC2trl+ stage I cluster was comparable to the BCL2trl+ cluster in stage III/IV. The two BCL2trl- stage I clusters were unique for stage I. One was enriched for CREBBP (95%) and STAT6 (64%) mutations, without BLC6 translocation (BCL6trl), whereas the BCL2trl- stage III/IV cluster contained BCL6trl (64%) with fewer CREBBP (45%) and STAT6 (9%) mutations. The other BCL2trl- stage I cluster was relatively heterogeneous with more copy number aberrations and linker histone mutations. This exploratory study shows that stage I FL is genetically heterogeneous with different underlying oncogenic pathways. Stage I FL BCL2trl- is likely STAT6 driven, whereas BCL2trl- stage III/IV appears to be more BCL6trl driven.
引用
- Los-de Vries GT, Stevens WBC, van Dijk E, et al. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV. Blood Adv. 2022. PMID: 35816682. doi:10.1182/bloodadvances.2022008355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。